Estrogen deprivation alters epigenetic modifications in breast cancer cells - HOXC10 loss in endocrine resistance

ABSTRACT: Postmenopausal breast cancer patients benefit from aromatase inhibitors (AIs) that reduce the levels of estrogens critical for the growth of estrogen receptor (ER)-positive tumors. Unfortunately, many tumors are resistant to AI, and we are only beginning to understand the complex mechanisms underlying treatment resistance. Here we set out to determine whether epigenetic changes could contribute to therapy resistance. For AI-resistance models, we used previously established MCF-7 cell clones, termed C4-12 and long-term estrogen deprivation (LTED), that were isolated after being cultured in estrogen-free media for 9 months and 18M-bM-^@M-^S24 months, respectively. Methyl CpG Binding Domain (MBD) - pull down followed by affymetrix promoter array was used to detect promoter methylation patt

ORGANISM(S): Homo sapiens

SUBMITTER: Yuanxin Xi 

PROVIDER: E-GEOD-39783 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress